Gram Negative Bacteremia, Risk Factors for Failure of Therapy

Study Results

Results pending

The study team has not published outcome measurements, participant flow, or safety data for this trial yet. Check back later for updates.

Basic Information

Get a concise snapshot of the trial, including recruitment status, study phase, enrollment targets, and key timeline milestones.

Recruitment Status

COMPLETED

Total Enrollment

600 participants

Study Classification

OBSERVATIONAL

Study Start Date

2005-04-30

Study Completion Date

2016-05-31

Brief Summary

Review the sponsor-provided synopsis that highlights what the study is about and why it is being conducted.

The aims of this study are to:

* Determine the risk factors for multidrug resistance in bloodstream isolates of Gram negative bacilli
* Determine the mechanisms of multidrug resistance in bloodstream isolates of Gram negative bacilli
* Determine the risk factors for failure of prompt clearance of the blood of Gram negative bacteria
* Determine the survival of patients with Gram negative bacteremia
* Determine if failure of prompt clearance of the blood of Gram negative bacteria is a predictor of mortality following this infection

Related Clinical Trials

Explore similar clinical trials based on study characteristics and research focus.

Trial for the Treatment of Extensively Drug-Resistant Gram-negative Bacilli (OVERCOME)

NCT01597973

Pneumonia Blood Stream Infection

COMPLETED PHASE3

Predictors of Rates of Resistant Gram-Negative Bacteria

NCT01075009

Relationship of Carbapenem Use to Carbapenem Resistant Gram-negative Bacteria

COMPLETED

Duration of Antibiotics for the Treatment of Gram-negative Bacilli Bacteremia

NCT01737320

Gram Negative Bacteremia

COMPLETED NA

Clinical Impact of Fluoroquinolone Resistance in Bacteremia Caused by Gram-Negative Bacilli of Urinary Tract Origin

NCT00414362

Urinary Tract Infection Fluoroquinolone Bacteremia

COMPLETED

Clinical Outcomes and Cost of Gram Negative Bacteremia

NCT02599220

Gram-negative Bacteremia Bacteremia

COMPLETED

Detailed Description

Dive into the extended narrative that explains the scientific background, objectives, and procedures in greater depth.

The following variables will be followed: time and location of positive cultures, underlying diseases and severity of illness, recent immunomodulative therapies, physical exam findings, laboratory and radiographical data, antimicrobial usage within 14 days of onset of bacteremia, microbiological data and resistance patterns, choice of antibiotics once organism identified, suspected source of bacteremia, bacteriological outcomes, laboratory results, demographic information, medications, clinical outcome,gender, height, weight, ethnicity, and past medical history (please see attached clinical data collection worksheet dated 4/2005). We will also collect information retrospectively for one year and prospectively for one year. The bacteria in the patient's blood cultures will be subcultured (after the diagnosis has been obtained since the microbiology lab would otherwise destroy the culture) and provided to the honest broker who will deidentify the specimen and link it to the medical information collected (which will also be deidentified by the honest broker). The following evaluation will be performed on these samples. The minimal inhibitory concentration of the antibiotic used in treatment will be performed by the E-Test method (AB Biodisk, Solna, Sweden). Specific mechanisms of antimicrobial resistance will be studied with emphasis on the presence of beta-lactamases produced by the bacteria. This evaluation will be performed by analytical isoelectric focusing techniques as well as PCR and gene sequencing analysis to determine genes encoding beta-lactamases. Biologic samples will be under the control of the principal investigator of this research project. All samples provided to the investigators are deidentified by the honest broker and will be coded with numbers. The information linking these code numbers to the corresponding subjects' identities will be kept in a separate, secure location that only the honest broker has access to. The investigators on this study will keep the samples indefinitely. Samples will be kept in the investigator's laboratory located in Scaife Hall, room 812, 3500 Terrace Street. At no time with the research investigators have access to any patient identifiers.

Conditions

See the medical conditions and disease areas that this research is targeting or investigating.

Gram-Negative Bacterial Infections

Study Design

Understand how the trial is structured, including allocation methods, masking strategies, primary purpose, and other design elements.

Observational Model Type

COHORT

Study Time Perspective

PROSPECTIVE

Eligibility Criteria

Check the participation requirements, including inclusion and exclusion rules, age limits, and whether healthy volunteers are accepted.

Inclusion Criteria

* All patients at the aforementioned institutions that have Gram negative bacteremia will be included in the study.
* Women with childbearing potential will also be included in this study. Since this is an observational study, no added risk is conferred to the woman or potential progeny. HIV serostatus will not be specifically investigated for participation in this study.